Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.

Veneziani I, Fruci D, Compagnone M, Pistoia V, Rossi P, Cifaldi L.

Oncotarget. 2019 Mar 15;10(22):2151-2160. doi: 10.18632/oncotarget.26736. eCollection 2019 Mar 15.

2.

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.

Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N.

Cancers (Basel). 2019 Mar 6;11(3). pii: E321. doi: 10.3390/cancers11030321.

3.

Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.

Boldrini R, De Pasquale MD, Melaiu O, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, Fruci D.

Oncoimmunology. 2018 Dec 13;8(2):e1542245. doi: 10.1080/2162402X.2018.1542245. eCollection 2019.

PMID:
30713803
4.

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.

Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F.

Front Immunol. 2018 Nov 28;9:2722. doi: 10.3389/fimmu.2018.02722. eCollection 2018. Review.

5.

Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma.

Horenstein AL, Morandi F, Bracci C, Pistoia V, Malavasi F.

Immunol Lett. 2019 Jan;205:40-50. doi: 10.1016/j.imlet.2018.11.007. Epub 2018 Nov 15. Review.

PMID:
30447309
6.

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.

Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F.

Oncoimmunology. 2018 May 7;7(8):e1458809. doi: 10.1080/2162402X.2018.1458809. eCollection 2018.

7.

CHL1 gene acts as a tumor suppressor in human neuroblastoma.

Ognibene M, Pagnan G, Marimpietri D, Cangelosi D, Cilli M, Benedetti MC, Boldrini R, Garaventa A, Frassoni F, Eva A, Varesio L, Pistoia V, Pezzolo A.

Oncotarget. 2018 May 25;9(40):25903-25921. doi: 10.18632/oncotarget.25403. eCollection 2018 May 25.

8.

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.

Pistoia V, Tumino N, Vacca P, Veneziani I, Moretta A, Locatelli F, Moretta L.

Front Immunol. 2018 May 7;9:984. doi: 10.3389/fimmu.2018.00984. eCollection 2018. Review.

9.

Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.

Veneziani I, Brandetti E, Ognibene M, Pezzolo A, Pistoia V, Cifaldi L.

J Immunol Res. 2018 Apr 1;2018:4972410. doi: 10.1155/2018/4972410. eCollection 2018.

10.

IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Ferretti E, Di Carlo E, Ognio E, Fraternali-Orcioni G, Corcione A, Belmonte B, Ravetti JL, Tripodo C, Ribatti D, Pistoia V.

Oncoimmunology. 2017 Nov 27;7(3):e1397249. doi: 10.1080/2162402X.2017.1397249. eCollection 2018.

11.

Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I.

Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017.

12.

Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients.

Ferretti E, Hohaus S, Di Napoli A, Belmonte B, Cuccaro A, Cupelli E, Galli E, Rufini V, Tripodi G, Fraternali-Orcioni G, Pistoia V, Corcione A.

Oncotarget. 2017 Jul 28;8(49):85263-85275. doi: 10.18632/oncotarget.19665. eCollection 2017 Oct 17.

13.

Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

Cifaldi L, Locatelli F, Marasco E, Moretta L, Pistoia V.

Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10. Review.

PMID:
29133133
14.

Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

Morandi F, Barco S, Stigliani S, Croce M, Persico L, Lagazio C, Scuderi F, Belli ML, Montera M, Cangemi G, Pozzi S, Rigo V, Scaruffi P, Amoroso L, Erminio G, Pistoia V, Ferrini S, Corrias MV.

Oncotarget. 2017 May 30;8(32):53194-53209. doi: 10.18632/oncotarget.18285. eCollection 2017 Aug 8.

15.

Use of luciferase probes to measure ATP in living cells and animals.

Morciano G, Sarti AC, Marchi S, Missiroli S, Falzoni S, Raffaghello L, Pistoia V, Giorgi C, Di Virgilio F, Pinton P.

Nat Protoc. 2017 Aug;12(8):1542-1562. doi: 10.1038/nprot.2017.052. Epub 2017 Jul 6.

PMID:
28683062
16.

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L.

Oncoimmunology. 2017 Apr 20;6(6):e1316439. doi: 10.1080/2162402X.2017.1316439. eCollection 2017.

17.

The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment.

Ferretti E, Corcione A, Pistoia V.

J Leukoc Biol. 2017 Sep;102(3):711-717. doi: 10.1189/jlb.3MR0117-033R. Epub 2017 Apr 13. Review.

PMID:
28408397
18.

Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Pezzolo A, Sementa AR, Lerone M, Morini M, Ognibene M, Defferrari R, Mazzocco K, Conte M, Gigliotti AR, Garaventa A, Pistoia V, Varesio L.

Cancer Biol Ther. 2017 May 4;18(5):285-289. doi: 10.1080/15384047.2017.1312231. Epub 2017 Apr 12.

19.

Mesenchymal stromal cells and autoimmunity.

Pistoia V, Raffaghello L.

Int Immunol. 2017 Feb 1;29(2):49-58. doi: 10.1093/intimm/dxx008. Review.

PMID:
28338763
20.

CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Morandi F, Pozzi S, Barco S, Cangemi G, Amoroso L, Carlini B, Pistoia V, Corrias MV.

Oncoimmunology. 2016 Oct 24;5(12):e1249553. doi: 10.1080/2162402X.2016.1249553. eCollection 2016.

21.

Editorial: Targeting JAM-C on mantle cell lymphoma B cells: time for clinical testing?

Pistoia V, Ferretti E.

J Leukoc Biol. 2016 Nov;100(5):835-837. No abstract available.

PMID:
27799440
22.

IL-17 superfamily cytokines modulate normal germinal center B cell migration.

Ferretti E, Ponzoni M, Doglioni C, Pistoia V.

J Leukoc Biol. 2016 Nov;100(5):913-918. Epub 2016 Aug 26. Review.

PMID:
27566830
23.

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Horenstein AL, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V, Giuliani N, Malavasi F.

Mol Med. 2016 Dec;22:694-704. doi: 10.2119/molmed.2016.00198. Epub 2016 Oct 13.

24.

Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases.

Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V.

J Immunol Res. 2016;2016:4326495. doi: 10.1155/2016/4326495. Epub 2016 Aug 29. Review.

25.

Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.

Morandi F, Pozzi S, Carlini B, Amoroso L, Pistoia V, Corrias MV.

J Immunol Res. 2016;2016:7465741. doi: 10.1155/2016/7465741. Epub 2016 Aug 16.

26.

"New insights into innate ad adaptive immunity from the European Congress of Immunology 2015".

Pistoia V.

Immunol Lett. 2016 Oct;178:1-2. doi: 10.1016/j.imlet.2016.08.005. Epub 2016 Aug 17. No abstract available.

PMID:
27544547
27.

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.

Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P.

Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):870.

28.

Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor.

Ceriolo P, Fausti V, Cinotti E, Bonadio S, Raffaghello L, Bianchi G, Orcioni GF, Fiocca R, Rongioletti F, Pistoia V, Borgonovo G.

World J Gastroenterol. 2016 Mar 28;22(12):3496-501. doi: 10.3748/wjg.v22.i12.3496.

29.

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R.

Oncoimmunology. 2015 Jul 15;5(1):e1064578. eCollection 2016.

30.

Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy.

Pistoia V, Pezzolo A.

J Immunol Res. 2016;2016:3142365. doi: 10.1155/2016/3142365. Epub 2016 Jan 27. Review.

31.

Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants.

Panfoli I, Ravera S, Podestà M, Cossu C, Santucci L, Bartolucci M, Bruschi M, Calzia D, Sabatini F, Bruschettini M, Ramenghi LA, Romantsik O, Marimpietri D, Pistoia V, Ghiggeri G, Frassoni F, Candiano G.

FASEB J. 2016 Apr;30(4):1416-24. doi: 10.1096/fj.15-279679. Epub 2015 Dec 11.

PMID:
26655706
32.

Isolation and characterization of renal cancer stem cells from patient-derived xenografts.

Hasmim M, Bruno S, Azzi S, Gallerne C, Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A, Pistoia V, Angevin E, Gad S, Ferlicot S, Messai Y, Kieda C, Clay D, Sabatini F, Escudier B, Camussi G, Eid P, Azzarone B, Chouaib S.

Oncotarget. 2016 Mar 29;7(13):15507-24. doi: 10.18632/oncotarget.6266.

33.

IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma.

Prigione I, Covone AE, Giacopelli F, Bocca P, Risso M, Tripodi G, Pistorio A, Sozzi G, Airoldi I, Ravazzolo R, Pistoia V.

Immunobiology. 2016 Feb;221(2):291-9. doi: 10.1016/j.imbio.2015.10.006. Epub 2015 Oct 29.

PMID:
26547104
34.

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, Tripodo C, Pistoia V.

Oncoimmunology. 2015 Jun 19;4(10):e1030560. eCollection 2015 Oct.

35.

Accumulation and translocation of heavy metal by spontaneous plants growing on multi-metal-contaminated site in the Southeast of Rio Grande do Sul state, Brazil.

Boechat CL, Pistóia VC, Gianelo C, Camargo FA.

Environ Sci Pollut Res Int. 2016 Feb;23(3):2371-80. doi: 10.1007/s11356-015-5342-5. Epub 2015 Sep 28.

PMID:
26411450
36.

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F.

Cells. 2015 Sep 17;4(3):520-37. doi: 10.3390/cells4030520. Review.

37.

Mesenchymal stromal cells and immunity: Introductory overview.

Moretta L, Uccelli A, Pistoia V.

Immunol Lett. 2015 Dec;168(2):127-8. doi: 10.1016/j.imlet.2015.08.010. Epub 2015 Sep 2. No abstract available.

PMID:
26342805
38.

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation.

Morandi F, Morandi B, Horenstein AL, Chillemi A, Quarona V, Zaccarello G, Carrega P, Ferlazzo G, Mingari MC, Moretta L, Pistoia V, Malavasi F.

Oncotarget. 2015 Sep 22;6(28):25602-18. doi: 10.18632/oncotarget.4693.

39.

Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Stigliani S, Croce M, Morandi F, Scaruffi P, Rigo V, Carlini B, Manzitti C, Gigliotti AR, Tonini GP, Pistoia V, Ferrini S, Corrias MV.

Biomed Res Int. 2015;2015:347867. doi: 10.1155/2015/347867. Epub 2015 Jun 16.

40.

CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.

Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, Zanellato S, Mortara L, Gattorno M, Pistoia V, Malavasi F.

J Immunol. 2015 Aug 1;195(3):965-72. doi: 10.4049/jimmunol.1500591. Epub 2015 Jun 19.

41.

Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.

Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.

J Control Release. 2015 Aug 10;211:44-52. doi: 10.1016/j.jconrel.2015.05.286. Epub 2015 May 29.

PMID:
26031842
42.

IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

Morandi F, Croce M, Cangemi G, Barco S, Rigo V, Carlini B, Amoroso L, Pistoia V, Ferrini S, Corrias MV.

J Immunol Res. 2015;2015:718975. doi: 10.1155/2015/718975. Epub 2015 Apr 19.

43.

Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models.

Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, Orengo A, Emionite L, Lavarello C, Amaro A, Petretto A, Pfeffer U, Sambuceti G, Pistoia V, Raffaghello L, Longo VD.

Oncotarget. 2015 May 20;6(14):11806-19.

44.

The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.

Amoroso F, Capece M, Rotondo A, Cangelosi D, Ferracin M, Franceschini A, Raffaghello L, Pistoia V, Varesio L, Adinolfi E.

Oncogene. 2015 Oct 8;34(41):5240-51. doi: 10.1038/onc.2014.444. Epub 2015 Jan 26.

PMID:
25619831
45.

γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes.

Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, Meazza R, Loiacono F, Lucarelli B, Bernardo ME, Barbarito G, Pende D, Moretta A, Pistoia V, Moretta L, Locatelli F.

Blood. 2015 Apr 9;125(15):2349-58. doi: 10.1182/blood-2014-09-599423. Epub 2015 Jan 22. Erratum in: Blood. 2016 Mar 24;127(12):1620.

46.

Intratumoral diversity of telomere length in individual neuroblastoma tumors.

Pezzolo A, Pistorio A, Gambini C, Haupt R, Ferraro M, Erminio G, De Bernardi B, Garaventa A, Pistoia V.

Oncotarget. 2015 Apr 10;6(10):7493-503.

47.

Accelerated tumor progression in mice lacking the ATP receptor P2X7.

Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D, Pinton P, Jorgensen NR, Abelli L, Emionite L, Raffaghello L, Pistoia V, Di Virgilio F.

Cancer Res. 2015 Feb 15;75(4):635-44. doi: 10.1158/0008-5472.CAN-14-1259. Epub 2014 Dec 26.

48.

Cancer associated fibroblasts in hematological malignancies.

Raffaghello L, Vacca A, Pistoia V, Ribatti D.

Oncotarget. 2015 Feb 20;6(5):2589-603. Review.

49.

Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.

Pezzolo A, Marimpietri D, Raffaghello L, Cocco C, Pistorio A, Gambini C, Cilli M, Horenstein A, Malavasi F, Pistoia V.

Oncotarget. 2014 Nov 15;5(21):10368-81.

50.

Evaluation of bone marrow as a metastatic site of human neuroblastoma.

Morandi F, Corrias MV, Pistoia V.

Ann N Y Acad Sci. 2015 Jan;1335:23-31. doi: 10.1111/nyas.12554. Epub 2014 Oct 14. Review.

PMID:
25315505

Supplemental Content

Loading ...
Support Center